Drugs / YZJ-5053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06209385 | Aug 2023 → Apr 2025 | neoplasm | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YZJ-5053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06209385 ↗ |
| Route | Oral | “YZJ-5053 tablets will be administrated orally QD for 21 days” NCT06209385 ↗ |